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ABSTRACT
Objective: The objective of the study was to show the efficacy of teriparatide in comminuted fracture healing and improvement in overall functional 
recovery.
Methods: A total of 30 subjects who suffered from comminuted fractures of lower limb were selected. Subjects were categorized into two groups: 
Group A (n=15) contained individuals with teriparatide administration and Group B (n=15) contained individuals who were not administered 
teriparatide. 20 mg of teriparatide was injected subcutaneously for a period of 3 months. Patients were followed up ay durations of 4, 8, and 12 weeks. 
Obtained data were entered into Microsoft Excel Worksheets and descriptive analysis was performed. Chi-square test was used to analyze all obtained 
data.
Results: Among Group A patients, the fracture healing rates were found to be significantly earlier with comparison to control group (Group B).
Conclusion: Teriparatide was observed to be effective in comminuted fracture healing and has demonstrated good clinical outcome.
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INTRODUCTION
Delayed fracture union or healing may be defined as a state wherein 
union of bone does not take place even following lapse of adequate 
time period from the tome of injury while non-union of fractured 
segments is the result of delay in union of fractures which as per the 
American Food and Drug Administration or FDA is a minimum period 
of 9 months. On the other hand, a comminuted fracture may be defined 
as a fracture with multiple bone fragments. It is caused by a crushing 
or compression force along the long axis of a bone. Although it is not 
possible to satisfy these criteria most of the times, a clinician makes 
use of clinical and radio-graphical parameters to define a non-union 
or delay in union of bone fractures [1]. There are various risk factors 
determining delayed as well as non-union of bone fractures- I. 
Factors specific to an individual: (a) Smoking; (b) uncontrolled 
diabetes; (c) infection; (d) advanced age; (e) hyperparathyroidism; 
(f) osteoporosis; (g) nutritional deficiencies - Vitamin D and Calcium; 
and (h) menopausal females II. Factors specific to fracture: (a) Minor 
trauma or injury; (b) sever loss of bone; (c) inadequate amount of 
fracture reduction and immobilization; (d) application of distraction; 
(e) inadequate vascular supply; (f) formation of massive hematoma; 
and (g) extended use of nonsteroidal anti-inflammatory drugs [1].
Parathyroid hormone (PTH) is an important regulator of metabolism 
of calcium and phosphorus. There are various types of analogues of 
PTH that are available commercially, for example, abaloparatide and 
teriparatide. Both are synthetic derivatives with a polypeptide and 
peptide derivation with 1-84 and 1-34 constitution [2]. Serum levels 
of teriparatide attain peak concentration in a time interval of 30 min 
which returns to undetectable levels within few hours. Thus, there is 
a transient increased formation of bone at sites of fracture. Thus, by 
increasing thickness of bone cortex and formation of new bone, this 
agent causes an increase in osteogenesis, thereby promoting healing of 
wound [3].
Teriparatide, a synthetic polypeptide hormone, is an anabolic 
drug which is constituted by 1-34 amino acid fragment of PTH of 
humans [4]. It is a N-terminal fragment of PTH [5]. The molecular mass 
of Teriparatide is 4117.8 Daltons. It is synthesized using the genetically 
modified Escherichia coli strain. It is available commercially in solution 
form of injecting subcutaneously. Treatment using teriparatide has 
demonstrated a significant increase in volume and mineralization of 
callus, increase in content of mineralized bone and increase in strength 
and rate of union of fractures [6]. Administration of PTH or teriparatide 
causes enhanced expression of Osterix in mesenchymal stem cells 
which leads to an increase in density of bone mineralization and 
increase in amount of fracture callus [7].
It causes an increase of remodeling and formation of bone. It also 
causes a reduction in fracture risk associated with vertebrae and other 
bones. In addition, it has been shown to cause an accelerated healing 
of bone fracture due to improvement in fractured callus. This results 
in an increase in remodeling of bone [4]. Effects on bone also include 
prevention of osteoblastic apoptosis [8].
Under teriparatide therapy, formation of fracture callus occurs 
in abundant quantity in a circumferential manner which appears 
cloud-like in radiographs and computed tomography (CT) scans [4].
Teriparatide results in an improvement in micro- as well as 
macro-architectural characteristics of osseous tissues. It is the first 
ever approved drug by the US FDA agency for osteoporosis. Healing of 
fracture wound is a process involving multiple pathways of signals that 
are regulated by a variety of local as well as systemic factors. A defect 
or an abnormality results in impairment in healing process which leads 
to non-union or delay in union. Factors which cause a delay in union 
may be mechanical or biological in nature or may be both. This drug 
causes an enhancement of the Wnt/β-catenin pathway which causes 
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regulation of collagen types II and X that determines callus size [9]. The 
effectiveness of teriparatide therapy is significantly associated with 
timing of drug delivery and fracture site as fractures undergo healing 
process by means of various mechanisms based on fracture location. 
This has been attributed to mechanical stimulation of affected bone. 
Hence, bones which are subjected to constant loading demonstrate 
more responsiveness to teriparatide therapy. Teriparatide mainly 
demonstrates its activity by stimulating formation of bone when 
compared to its resorption. This is termed as “anabolic index” of the 
drug. Teriparatide acts by promoting proliferation and differentiation 
of chondro as well as osteo-progenitor mesenchymal origin stem cells, 
maturation of chondrocytes, bone matrix protein production and 
formation of osteoclasts or osteoclastogenesis [10,11].
Treatment of non-union fractures using teriparatide helps patients to 
avoid undergoing another surgical procedure and problems associated 
with auto-grafts such as injury or pain to donor site or neurovascular 
damage [12]. Side effects include - nausea, headache, and vomiting. 
However, continuous administration of teriparatide increases risk 
of osteosarcoma, Paget’s disease, and elevated levels of alkaline 
phosphatase. Local side effects at site of injection include - pain, itching, 
swelling, and erythema. It can also cause an increase in serum levels of 
uric acid; hence, it should be prescribed with caution in patients with 
renal disease impairment [12].
Absolute contraindications for usage of teriparatide 
are - Paget’s disease of bone, both primary as well as secondary 
hyperparathyroidism, increased alkaline phosphatase levels, 
open epiphyseal ends among children, end-organ failure, 
pregnancy and lactation, metastatic malignancy of skeleton, and 
prior radiotherapy [13,14]. Thus, the aim of this study was to 
retrospectively analyze the efficacy of teriparatide administration in 
comminuted fracture healing in lower limbs.
METHODS
This retrospective study was performed to evaluate effects of daily 
administration of teriparatide on comminuted fracture wound healing 
in the lower limbs. The study was conducted after obtaining permission 








30 patients, 15 patients in each group.
Methodology
30 patients were selected through purposive sampling and were 
subsequently, categorized in two groups which contained 15 patients 
each. Group A comprised subjects with comminuted fractures who 
were administered Teriparatide on a daily basis while Group B 
comprised patients with comminuted fractures with no teriparatide 
administration.
Inclusion criteria
(a) Subjects within age range of 18–65 years and (b) subjects with 
comminuted fractures of lower limb were included in the study.
Exclusion criteria
(a) Old and non-operated fractures; (b) patient aged <18 years and 
more than 65 years; (c) pregnant and lactating female subjects; and 
(d) comminuted fracture other than lower limb were excluded from the 
study.
Teriparatide is available as Pen injection which is easily 
self-administered. 20 mcg dose was administered subcutaneously on a 
daily basis for a duration of 3 months.
Outcome measures
Outcome measures were dependent on - (a) Radiological features 
assessed by X-ray and CT scan and (b) functional outcome - weight 
bearing capacity. Post-operative follow-up was performed at 4, 8, and 
12 weeks duration.
Data analysis
Obtained data were entered into Microsoft Excel 2007 worksheets 
and descriptive analysis was carried out. Chi-square test was used to 
analyze the obtained data and p-value <0.05 was considered to have 
statistical significance.
RESULTS
Out of 15 patients in Group A, that is, patients who were treated using 
teriparatide for 3 months duration, the healing rates were found to 
be significantly earlier (p<0.001) when compared to control group 
(Group B). Fracture union was seen to occur in nine patients with 
no visible fracture line in Group A. During the follow-up of Group B 
patients who did not receive teriparatide, six had to undergo bone-
grafting surgery for achieving fracture union, six had union of fracture 
with visible fracture line and became pain-free following 2 months 
of postoperatively while three subjects demonstrated continuous 
pain and poor fracture healing. Subjects treated with teriparatide 
(mean=3.6 months) demonstrated earlier mobilization compared to 
those without (mean=4.5 months) (p=0.02) (Table 1 and Graph 1).
DISCUSSION
Osteoanabolic drugs are agents that aid in formation of bone hence; they 
are used for facilitating healing of fractures. A newer category of drugs 
acts by targeting sclerosis which causes inhibition of formation of bone. 
It is found to be expressed within osteocytes. An osteoanabolic effect 
may be achieved by blockage of sclerostin expression. Furthermore, 
bone which is formed following administration of anti-sclerosing agent 
is not get lost due to disuse atrophy [15,16].
In our study, an enhanced fracture healing was observed in subjects 
treated with teriparatide on a daily basis when compared to those 
who did not receive the drug therapy. Our findings are corroborated by 
Table 1: P-values of parameters studied on comparing both the 
study groups
Parameters studied p-values


























Graph 1: Demonstrating mobilization period in both groups 
studied
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radiological assessment as well as relatively early mobilization of the 
patients in treated individuals. Our findings have been supported by 
various investigators as described in following paragraphs.
Mishra et al. in 2019 in their prospective study on use of teriparatide on 
delayed union of bone fracture demonstrated enhanced healing of fracture 
wound [9]. Kim et al. in 2019 in their study showed that teriparatide 
treatment caused significant increase in Harris Hip Score (p=0.02) and 
reduction in visual analogue pain scale score (p=0.0005). The mean 
post-operative time required for healing of fracture was found to decrease 
in patient treatment with teriparatide when compared to those who did 
not receive this therapy (i.e., 12.1 and 14.8 weeks, respectively) [10].
Yukata et al. in 2018 in their study showed that a continuous PTH1-34 
administration or infusion led to a delay in healing of a fracture wound 
due to delay in maturation of callus [11]. Saraf and Munot in 2017 
demonstrated that fractures which were treated with 20 µg dosage of 
teriparatide demonstrated only signs of union associated with large 
amount of callus formation with significant reduction in radiographic 
union and early patient rehabilitation [12]. Bhandari et al. in 2016 
also reported that only 15% of patients suffering from hip fractures 
with internal fixation who were administered teriparatide required 
revision surgery. Higher percentage of patients who were treated with 
teriparatide demonstrated early ambulation and regained prefracture 
movements within a duration of 12 months [16].
Kim et al. in 2015 reported effects of teriparatide administration on 
osteoporosis subjects. They reported formation of fracture associated 
callus at an early stage of healing which continued up to 8 weeks and 
eventually led to healing of bone fracture. Normal bone remodeling was 
noted on 1 year post-operative follow-up [4]. Chiang et al. in 2013 in their 
study demonstrated that daily subcutaneous injection of teriparatide in 
dosage of 20 mg was associated with 2 to 3 times increase in expression 
of markers linked with remodeling of bone and healing of fracture [17].
Gomberg et al. in 2011 demonstrated that daily administration of 
teriparatide subcutaneously causes an increase in serum biomarker 
levels of formation of bone within a time span of 1 to 2 months while the 
markers of bone resorption demonstrate an increase in 2 to 3 months 
among subjects suffering from osteoporosis [18].
CONCLUSION
Teriparatide is an anabolic drug which is synthesized as a recombinant 
PTH analog. It has demonstrated efficacy in wound healing in 
osteoporotic subjects suffering from fractures, its efficacy in treating 
complicated fracture union has not been explored widely. This study has 
demonstrated that teriparatide can be used as an agent even in cases 
with comminuted bone fractures not only in enhancing healing period 
but also, in decreasing the time for mobilization or functional loading.
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